Fig 1.
Flow chart of patient selection.
Table 1.
Patient characteristics between AI (+) and AI (-) groups.
Fig 2.
Forest plot of the association between potential risk factors and immune-related adverse events.
(a) Multivariate logistic regression analysis. (b) Univariate analysis. OR odds ratio; CI confidence interval; HCC hepatocellular carcinoma; RCC renal cell carcinoma; HNSCC head and neck squamous cell carcinoma; CR complete response; PR partial response; SD stable disease; PD progressive disease; NE; not evaluable.
Fig 3.
Forest plot of the association between potential risk factors and ICI discontinuation due to irAE.
(a) Multivariate logistic regression analysis. (b) Univariate analysis. The abbreviations are the same with Fig 1.
Fig 4.
Kaplan-Meier curve of irAE-free survival between the patients with pre-existing autoimmune disease (AI) and those without it.
The onset of irAE or death due to any reasons was considered as an event, whichever comes first. The median irAE-free survival time was significantly shorter in the AI (+) group compared to the AI (-) group (5.7 months [95% CI: 3.5–7.8] vs. 10.4 months [95% CI: 7.90–12.9], p = 0.035). AI (+) group; n = 28 (censored case 4), AI (-) group; n = 450 (censored case 135).
Table 2.
Type of irAEs and the grades in all cases.
Table 3.
Comparison of the patient characteristics between irAE (+) and (-) groups among the 28 patients accompanied with autoimmune diseases (AI).
Fig 5.
Swimmer’s plot of irAE (+) cases in AI (+) patients.
Red rectangle; onset of de novo irAE, black circle; onset of AI flare, green square; the time of ICI discontinuation due to irAE, arrow head; ICI continuation at the time of data cut-off. One re-challenged case (no. 13) was omitted because continuation of AI flare at the initiation of the second ICI challenge.
Table 4.
Type and grade of irAEs in AI (+) cases.